Literature DB >> 19092136

Cannabinoid CB1 receptor antagonists for atherosclerosis and cardiometabolic disorders: new hopes, old concerns?

Pál Pacher.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19092136      PMCID： PMC2669438          DOI： 10.1161/ATVBAHA.108.178129

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN： 1079-5642            Impact factor:   8.311


× No keyword cloud information.
  22 in total

Review 1.  Role of monocytes in atherogenesis.

Authors:  Bjarne Osterud; Eirik Bjorklid
Journal:  Physiol Rev       Date:  2003-10       Impact factor: 37.312

2.  Pharmacological inhibition of CB1 cannabinoid receptor protects against doxorubicin-induced cardiotoxicity.

Authors:  Partha Mukhopadhyay; Sándor Bátkai; Mohanraj Rajesh; Nora Czifra; Judith Harvey-White; György Haskó; Zsuzsanna Zsengeller; Norma P Gerard; Lucas Liaudet; George Kunos; Pál Pacher
Journal:  J Am Coll Cardiol       Date:  2007-07-23       Impact factor: 24.094

3.  Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia.

Authors:  Jean-Pierre Després; Alain Golay; Lars Sjöström
Journal:  N Engl J Med       Date:  2005-11-17       Impact factor: 91.245

4.  Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study.

Authors:  Luc F Van Gaal; Aila M Rissanen; André J Scheen; Olivier Ziegler; Stephan Rössner
Journal:  Lancet       Date:  2005 Apr 16-22       Impact factor: 79.321

Review 5.  The endocannabinoid system as an emerging target of pharmacotherapy.

Authors:  Pál Pacher; Sándor Bátkai; George Kunos
Journal:  Pharmacol Rev       Date:  2006-09       Impact factor: 25.468

Review 6.  Cytokines in atherosclerosis: pathogenic and regulatory pathways.

Authors:  Alain Tedgui; Ziad Mallat
Journal:  Physiol Rev       Date:  2006-04       Impact factor: 37.312

7.  Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study.

Authors:  André J Scheen; Nick Finer; Priscilla Hollander; Michael D Jensen; Luc F Van Gaal
Journal:  Lancet       Date:  2006-11-11       Impact factor: 79.321

8.  Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight/obese patients: pooled 1-year data from the Rimonabant in Obesity (RIO) program.

Authors:  Luc Van Gaal; Xavier Pi-Sunyer; Jean-Pierre Després; Christine McCarthy; André Scheen
Journal:  Diabetes Care       Date:  2008-02       Impact factor: 19.112

9.  Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial.

Authors:  F Xavier Pi-Sunyer; Louis J Aronne; Hassan M Heshmati; Jeanne Devin; Julio Rosenstock
Journal:  JAMA       Date:  2006-02-15       Impact factor: 56.272

10.  Rimonabant reduces obesity-associated hepatic steatosis and features of metabolic syndrome in obese Zucker fa/fa rats.

Authors:  Magali Gary-Bobo; Ghizlane Elachouri; Jean François Gallas; Philip Janiak; Pietro Marini; Christine Ravinet-Trillou; Michèle Chabbert; Noël Cruccioli; Christian Pfersdorff; Claude Roque; Michèle Arnone; Tiziano Croci; Philippe Soubrié; Florence Oury-Donat; Jean Pierre Maffrand; Bernard Scatton; Frederic Lacheretz; Gérard Le Fur; Jean Marc Herbert; Mohammed Bensaid
Journal:  Hepatology       Date:  2007-07       Impact factor: 17.425
View more
  15 in total

1.  Fatty acid amide hydrolase is a key regulator of endocannabinoid-induced myocardial tissue injury.

Authors:  Partha Mukhopadhyay; Bėla Horváth; Mohanraj Rajesh; Shingo Matsumoto; Keita Saito; Sándor Bátkai; Vivek Patel; Galin Tanchian; Rachel Y Gao; Benjamin F Cravatt; György Haskó; Pál Pacher
Journal:  Free Radic Biol Med       Date:  2010-11-09       Impact factor: 7.376

2.  Cannabidiol protects against hepatic ischemia/reperfusion injury by attenuating inflammatory signaling and response, oxidative/nitrative stress, and cell death.

Authors:  Partha Mukhopadhyay; Mohanraj Rajesh; Béla Horváth; Sándor Bátkai; Ogyi Park; Galin Tanchian; Rachel Y Gao; Vivek Patel; David A Wink; Lucas Liaudet; György Haskó; Raphael Mechoulam; Pál Pacher
Journal:  Free Radic Biol Med       Date:  2011-03-11       Impact factor: 7.376

3.  CB1 cannabinoid receptors promote oxidative/nitrosative stress, inflammation and cell death in a murine nephropathy model.

Authors:  Partha Mukhopadhyay; Hao Pan; Mohanraj Rajesh; Sándor Bátkai; Vivek Patel; Judith Harvey-White; Bani Mukhopadhyay; György Haskó; Bin Gao; Ken Mackie; Pál Pacher
Journal:  Br J Pharmacol       Date:  2010-06       Impact factor: 8.739

4.  Cannabinoid-1 receptor activation induces reactive oxygen species-dependent and -independent mitogen-activated protein kinase activation and cell death in human coronary artery endothelial cells.

Authors:  Mohanraj Rajesh; Partha Mukhopadhyay; György Haskó; Lucas Liaudet; Ken Mackie; Pál Pacher
Journal:  Br J Pharmacol       Date:  2010-06       Impact factor: 8.739

5.  Newer antiatherosclerosis treatment strategies.

Authors:  Amitesh Aggarwal; Safal Singh
Journal:  Heart Asia       Date:  2011-01-01

Review 6.  Cannabimimetic phytochemicals in the diet - an evolutionary link to food selection and metabolic stress adaptation?

Authors:  Jürg Gertsch
Journal:  Br J Pharmacol       Date:  2017-01-16       Impact factor: 8.739

7.  Targeting cannabinoid receptor CB(2) in cardiovascular disorders: promises and controversies.

Authors:  Sabine Steffens; Pál Pacher
Journal:  Br J Pharmacol       Date:  2012-09       Impact factor: 8.739

Review 8.  Cardiovascular effects of marijuana and synthetic cannabinoids: the good, the bad, and the ugly.

Authors:  Pal Pacher; Sabine Steffens; György Haskó; Thomas H Schindler; George Kunos
Journal:  Nat Rev Cardiol       Date:  2017-09-14       Impact factor: 32.419

Review 9.  The emerging role of the endocannabinoid system in cardiovascular disease.

Authors:  Pál Pacher; Sabine Steffens
Journal:  Semin Immunopathol       Date:  2009-04-09       Impact factor: 9.623

10.  Endogenous cannabinoid receptor CB1 activation promotes vascular smooth-muscle cell proliferation and neointima formation.

Authors:  Filippo Molica; Fabienne Burger; Aurélien Thomas; Christian Staub; Anne Tailleux; Bart Staels; Graziano Pelli; Andreas Zimmer; Benjamin Cravatt; Christian M Matter; Pal Pacher; Sabine Steffens
Journal:  J Lipid Res       Date:  2013-03-11       Impact factor: 5.922
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.